In the dynamic realm where technology meets humanity, we are seeing a new frontier called digital twins. These AI-driven entities, also known as digital humans or synthetic clones, are reshaping the future of education, research, and training across nearly every sector, including the pharmaceutical and life sciences industries.
Tag Archive for: drug discovery
Artificial intelligence (AI) surely stands at the forefront of one of the most transformative periods in the pharmaceutical industry. Its rapid drug discovery capabilities and potential for personalized patient care mark AI as a revolutionary influence in reshaping the pharmaceutical industry. Central to this transformation is natural language processing (NLP).
The new facility in Rockville, Maryland will focus on manufacturing for critical cancer trials and launch of its commercial cell therapy platforms.
No longer on the periphery of the life sciences market, nonprofit groups are bridging the gaps in drug discovery and development.
As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.
2024 will continue to see Big Tech companies enter the artificial intelligence-based drug discovery space, potentially disrupting the biopharma industry. That was the consensus of panelists at a Tuesday session on AI and machine learning held by the Biotech Showcase, co-located with the 42nd J.P. Morgan Healthcare Conference.
Biomedical research, the bedrock of medical advancements on Earth, has always been a maze of challenges. From the complexities of human biology to the unpredictability of diseases, researchers are in a constant battle with variables that can alter the course of a study. But what if there was a way to sidestep some of these Earth-bound limitations? This is where space, the next frontier in clinical research, comes into play.
In recent years, J&J has pumped hundreds of millions of dollars into its artificial intelligence (AI) capabilities, according to the WSJ, including bringing on some 6,000 data science and digital specialists and erecting a “cutting-edge” research facility in the San Francisco Bay Area, which it opened in September 2022.
The U.S. medical equipment maker is looking to boost its life sciences portfolio that helps in drug discovery.
Moderna said the companies would use Immatics’ drug discovery platform to develop mRNA-based cancer vaccines, and also study its own cancer vaccine for use in combination with Immatics’ cancer therapy IMA203.
